University Teaching Department (Pharmacy), Sarguja University, Ambikapur (Chhattisgarh) 497001, India.
Rungta College of Pharmaceutical Sciences and Research, Bhilai, Chhattisgarh 490024, India.
Curr Stem Cell Res Ther. 2019;14(2):146-151. doi: 10.2174/1574888X13666181002154110.
Diabetes and its complications are a significant health concern throughout the globe. There are physiological differences in the mechanism of type-I and type-II diabetes and the conventional drug therapy as well as insulin administration seem to be insufficient to address the problem at large successfully. Hypoglycemic swings, frequent dose adjustments and resistance to the drug are major problems associated with drug therapy. Cellular approaches through stem cell based therapeutic interventions offer a promising solution to the problem. The need for pancreatic transplants in case of Type- I diabetes can also be by-passed/reduced due to the formation of insulin producing β cells via stem cells. Embryonic Stem Cells (ESCs) and induced Pluripotent Stem Cells (iPSCs), successfully used for generating insulin producing β cells. Although many experiments have shown promising results with stem cells in vitro, their clinical testing still needs more exploration. The review attempts to bring into light the clinical studies favoring the transplantation of stem cells in diabetic patients with an objective of improving insulin secretion and improving degeneration of different tissues in response to diabetes. It also focuses on the problems associated with successful implementation of the technique and possible directions for future research.
糖尿病及其并发症是全球范围内的一个重大健康问题。1 型和 2 型糖尿病的发病机制存在生理差异，传统的药物治疗和胰岛素给药似乎不足以成功解决这个问题。低血糖波动、频繁调整剂量和对药物的耐药性是药物治疗的主要问题。通过基于干细胞的治疗干预的细胞方法为该问题提供了一个有前途的解决方案。由于通过干细胞形成产生胰岛素的β细胞，因此可以避免/减少 1 型糖尿病患者对胰腺移植的需求。胚胎干细胞 (ESC) 和诱导多能干细胞 (iPSC) 已成功用于产生产生胰岛素的β细胞。尽管许多实验已经证明了干细胞在体外具有有前途的结果，但它们的临床测试仍需要更多的探索。本综述旨在阐明支持将干细胞移植到糖尿病患者中的临床研究，以提高胰岛素分泌并改善糖尿病引起的不同组织的退化。它还侧重于成功实施该技术相关的问题以及未来研究的可能方向。
